Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Abstract:
Un anticuerpo monoclonal neutralizante aislado, o un fragmento de unión al antígeno del mismo, que interactúan específicamente al menos con un epítopo del receptor de Nogo-66, donde el anticuerpo monoclonal neutralizante aislado, o un fragmento de unión al antígeno del mismo , comprende una secuencia que comprende una región variable de cadena pesada (región VH) que comprende SEQ ID NO: 3 y una secuencia que comprende una región variable de cadena ligera (región VL) que comprende SEQ ID NO: 4, o una secuencia que comprende una región variable de cadena pesada (región VH) que comprende SEQ ID NO: 5 y una secuencia que comprende una región variable de cadena ligera (región VL) que comprende SEQ ID NO: 6.
Abstract:
The subject invention relates to isolated proteins, particularly monoclon al antibodies, which bind to the Nogo-66 receptor. Specifically, these antib odies have the ability to inhibit the binding of the natural ligand of the N ogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or por tions thereof of the invention are useful for detecting NgR and for inhibiti ng NgR activity, for example in a human suffering from a disorder in which N gR or Nogo-66 activity is detrimental.
Abstract:
El tema de la invención se relaciona con proteínas aisladas particularmente anticuerpos monoclonales, los cuales se unen con el receptor de Nogo-66. Específicamente, los anticuerpos tienen la capacidad de inhibir la unión del ligando natural del receptor de Nogo-66 y neutralizar el receptor de Nogo-66. Estos anticuerpos o porciones de los mismos de la invención son útiles par detectar NgR y para inhibir la actividad de NgR, por ejemplo, en un ser humano que padece un trastorno en el que la actividad de NgR o Nogo-66 es perjudicial.